<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=461926130648047&ev=PageView&noscript=1"> QIAstat-Dx Syndromic Testing Webinar
QIAGEN

Learn about the role of multiplex testing in the COVID-19 pandemic

Title: Tackling COVID-19 through syndromic testing – QIAstat-Dx Respiratory SARS-CoV-2 Panel

Speaker: Davide Manissero, MD, MRCPCH, MSc, DTM&H,  VP Head of Medical Affairs & Chief Medical Officer, Infection & Immune Diagnostics, QIAGEN

During this webinar, QIAGEN Chief Medical Officer Dr. Davide Manissero will discuss the role of multiplex respiratory PCR testing in the ongoing COVID-19 pandemic and how QIAGEN ramped up development efforts to be the first syndromic solution on the market. The importance of time to diagnosis and potential for co-infections as we approach the 2020-2021 influenza season will be discussed.

For more information, visit www.qiastat-dx.com.

I hereby give QIAGEN the consent to contact me via email and phone (subject to the contact information provided above) with further contests, special offers and product information.*

* Disclaimer: 
The QIAstat-Dx Respiratory SARS-CoV-2 Panel is intended for in vitro diagnostic use.

  • Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity and moderate complexity tests.
  • This test has not been FDA cleared or approved;
  • This test has been authorized by FDA under an EUA for use by authorized laboratories;
  • This test has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and
  • This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Subject to your consent given above, QIAGEN may use your personal information for internal business and marketing purposes. The information will not be sold to any third party. QIAGEN may transfer your personal information to our CRM system (hosted by SalesForce.com, Inc. and Oracle Corp.) solely for the purposes of data hosting and QIAGEN email distribution. You may unsubscribe at any time. Your data will be processed in compliance with applicable privacy laws including the EU General Data Protection Regulation. For further details please refer to our Privacy Policy